Shanghai Henlius Advances Anti‑IL1RAP Antibody HLX109 Toward First‑in‑Human Trial – Australian HREC Approval and TGA CTN Completed for Generalized Pustular Psoriasis

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that HLX109, its innovative anti‑IL1RAP monoclonal antibody, has received approval from the Human Research Ethics Committee (HREC) in Australia and completed the Clinical Trial Notification (CTN) with the Therapeutic Goods Administration (TGA) – clearing the path for a planned clinical trial in patients with generalized pustular psoriasis (GPP).

Regulatory Milestone

Drug Profile & Mechanism of Action

• Molecule: HLX109, a potential best‑in‑class (BIC) IL1RAP‑targeting monoclonal antibody candidate independently developed by Henlius.
• Target: IL1RAP, a key co‑receptor of the IL‑1 family required for signaling by multiple pro‑inflammatory cytokines.
• Mechanism: By specifically binding IL1RAP, HLX109 is designed to block the interaction of IL‑1, IL‑33, and IL‑36 cytokines with their receptor complexes, thereby inhibiting downstream inflammatory signaling activation.
• Differentiation vs. IL‑36R Agents: Unlike approaches targeting the IL‑36 receptor alone – the validated mechanism in approved GPP therapies – HLX109 has the potential to simultaneously modulate multiple key IL‑1 family inflammatory pathways, offering a broader approach to regulating inflammatory responses.
• Formulation Innovation: HLX109 features a unique molecular design and incorporates a recombinant human hyaluronidase independently developed by Henlius as an excipient, formulated for subcutaneous administration.
• Non‑Clinical Profile: Non‑clinical studies indicate superior pharmacokinetic (PK) and pharmacodynamic (PD) profiles as well as a favorable safety profile; quantitative data not disclosed.

Clinical Development Plan – GPP Trial

• Population: Patients with generalized pustular psoriasis, a rare, severe, and potentially life‑threatening neutrophilic skin disease characterized by recurrent flares of widespread sterile pustules.
• Setting: Australia, leveraging the HREC/TGA CTN pathway – a route frequently used by Chinese biotechs to initiate first‑in‑human or early‑phase studies under internationally recognized GCP standards.
• Design: Trial phase, dosing regimen, primary endpoints, sample size, and timelines were not disclosed in the announcement.

Market Impact & Outlook

• Beyond IL‑36R: With anti‑IL‑36R therapy established as the standard for GPP flares, a multi‑pathway upstream blockade via IL1RAP could address residual inflammatory drive from IL‑1 and IL‑33 signaling, positioning HLX109 as a potential best‑in‑class successor in acute and maintenance GPP management.
• Autoimmune Pipeline Depth: The milestone extends Henlius’s innovative‑drug pipeline beyond its biosimilar foundation, reinforcing its transition toward first‑in‑house novel biologics in immunology and inflammation.
• Subcutaneous Convenience: The proprietary hyaluronidase‑enabled subcutaneous formulation targets easier administration – a competitive consideration in chronic inflammatory dermatoses where infusion‑based care burdens patients.
• Global Strategy: Australia as the launchpad for clinical development suggests an intent to build internationally acceptable datasets, supporting future filings in multiple jurisdictions; partnership and regional commercialization plans were not disclosed.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding HLX109’s clinical development, regulatory timelines, and therapeutic potential in generalized pustular psoriasis and other inflammatory conditions. Non‑clinical findings may not predict human outcomes. Actual results may differ materially due to risks including trial execution and enrollment, safety and efficacy in humans, regulatory decisions, and competitive dynamics in the immunology market.-Fineline Info & Tech